A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Timothy Hagerty
Advertisement
Timothy Hagerty is scientist at Pfizer Global Research and Development Global Biologics, Bioprocess R&D
Articles by Timothy Hagerty
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
4
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
5